By Joe Hoppe
Silence Therapeutics PLC said Monday that its shareholders voted to approve the cancellation of its listing on London's junior AIM, keeping a single listing on New York's Nasdaq.
The medical company said on Oct. 15 that it would seek shareholder approval to delist, adding that the move would enhance liquidity in its American Depositary Shares and increase U.S. investors' willingness to invest in the company.
The last day of trading is expected to be Nov. 29.
Write to Joe Hoppe at joseph.hoppe@wsj.com